IGF-I Investigated for Impact on Body Composition, Glucose, and Lipids in HIV Metabolic Disease

HIV metabolic disease, often termed HIV lipodystrophy, is a complex syndrome affecting individuals with HIV infection, particularly those on antiretroviral therapy (ART). It manifests as changes in body fat distribution (lipoatrophy and/or lipohypertrophy), dyslipidemia, and insulin resistance, significantly increasing the risk of cardiovascular disease and type 2 diabetes. Current management often involves lifestyle modifications and switching ART regimens, but these approaches have limited efficacy in fully reversing the metabolic abnormalities. There is a critical need for targeted therapies that can address the underlying pathophysiology of these metabolic disturbances, which are thought to involve chronic inflammation and altered growth hormone/IGF-1 axis signaling.

This study investigated the effects of recombinant insulin like growth factor - I in adults diagnosed with HIV infection and exhibiting signs of metabolic disease. The research aimed to assess the intervention's impact across several key metabolic parameters, including body composition, glucose homeostasis, and lipid profiles. The abstract does not specify the study design (e.g., randomized controlled trial, observational), the number of participants (n), the exact dosage or route of administration for the IGF-I, nor the duration of the intervention. Similarly, specific primary endpoints or the nature of any control arm were not detailed in the provided information.

The provided abstract only states the study's purpose and does not present any findings, results, or data points. Therefore, no specific numerical outcomes, statistical significances (p-values), or fold-changes can be reported for this study.